News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,184 Results
Type
Article (13976)
Company Profile (299)
Press Release (247909)
Section
Business (79594)
Career Advice (160)
Deals (13212)
Drug Delivery (35)
Drug Development (50357)
Employer Resources (33)
FDA (5695)
Job Trends (5135)
News (144453)
Policy (10038)
Tag
Academia (905)
Alliances (21570)
Alzheimer's disease (750)
Approvals (5669)
Artificial intelligence (67)
Bankruptcy (100)
Best Places to Work (4534)
Biotechnology (245)
Breast cancer (108)
Cancer (857)
Cardiovascular disease (67)
Career advice (141)
CAR-T (68)
Cell therapy (208)
Clinical research (40093)
Collaboration (279)
Compensation (121)
COVID-19 (1006)
C-suite (76)
Cystic fibrosis (66)
Data (960)
Diabetes (81)
Diagnostics (1206)
Earnings (29023)
Events (47216)
Executive appointments (227)
FDA (6039)
Funding (292)
Gene editing (63)
Gene therapy (161)
GLP-1 (306)
Government (1069)
Healthcare (6558)
Infectious disease (1042)
Inflammatory bowel disease (98)
IPO (7196)
Job creations (863)
Job search strategy (133)
Layoffs (187)
Legal (1378)
Lung cancer (123)
Lymphoma (57)
Manufacturing (80)
Medical device (2568)
Medtech (2569)
Mergers & acquisitions (6134)
Metabolic disorders (243)
Neuroscience (987)
NextGen Class of 2024 (2018)
Non-profit (856)
Northern California (1054)
Obesity (134)
Opinion (91)
Parkinson's disease (70)
Patents (59)
People (25193)
Phase I (14119)
Phase II (18639)
Phase III (11815)
Pipeline (358)
Postmarket research (857)
Preclinical (5969)
Radiopharmaceuticals (205)
Rare diseases (196)
Real estate (1416)
Regulatory (8270)
Research institute (934)
Southern California (949)
Startups (1967)
United States (8407)
Vaccines (164)
Weight loss (78)
Date
Today (50)
Last 7 days (435)
Last 30 days (1673)
Last 365 days (20576)
2024 (20085)
2023 (22427)
2022 (26906)
2021 (27924)
2020 (23474)
2019 (16301)
2018 (11809)
2017 (13774)
2016 (11860)
2015 (14367)
2014 (10420)
2013 (7499)
2012 (7575)
2011 (7644)
2010 (7446)
Location
Africa (150)
Asia (16918)
Australia (2853)
California (2390)
Canada (785)
China (195)
Colorado (88)
Connecticut (99)
Europe (36451)
Florida (261)
Georgia (68)
Illinois (145)
Indiana (60)
Kansas (55)
Maryland (320)
Massachusetts (1898)
Michigan (54)
Minnesota (99)
New Jersey (609)
New York (666)
North Carolina (414)
Northern California (1054)
Ohio (81)
Pennsylvania (459)
South America (210)
Southern California (949)
Texas (267)
Washington State (243)
262,184 Results for "accent therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting
Accent Therapeutics presents advances in cancer targeting at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
April 8, 2024
·
6 min read
Press Releases
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
October 24, 2024
·
5 min read
Genetown
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing.
January 23, 2024
·
5 min read
Genetown
Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced four upcoming presentations and posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
March 21, 2024
·
4 min read
Business
Accent Therapeutics Bolsters Leadership Team with Key Executive Hires
Accent Therapeutics today announced the appointments of Jason Sager, M.D. as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.
September 21, 2023
·
5 min read
Genetown
Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium
Accent Therapeutics today announced it will present data unveiling a novel, previously undisclosed program in two poster presentations at the 35th AACR-NCI-EORTC Symposium held October 11-15, 2023 in Boston, Massachusetts.
October 10, 2023
·
6 min read
Genetown
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
Accent Therapeutics presented data supporting DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.
April 16, 2023
·
4 min read
Genetown
Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
Accent Therapeutics today announced an upcoming presentation introducing DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
April 6, 2023
·
2 min read
Drug Development
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
Ipsen and Accent Therapeutics have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program.
October 18, 2021
·
8 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 26,219
Next
